Company / Operating Income
AIM ImmunoTech Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$11.7M
FY2025
5-year range
-$31.9M / -$11.7M
FY2021-FY2025
Trend
+63.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income returned to growth in FY2025 after 3 years of decline, reaching -$12M.
Based on SEC 10-K filings.
-$12M in FY2025.
Improved from -$20M to -$12M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 63.5% year-over-year.
- Peak operating income was recorded in FY2018.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -71.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$11.7M | +63.5% |
| FY2024 | -$31.9M | -60.2% |
| FY2023 | -$19.9M | -5.8% |
| FY2022 | -$18.8M | -24.3% |
| FY2021 | -$15.2M | +0.0% |
| FY2020 | -$15.2M | -21.8% |
| FY2019 | -$12.4M | -8.2% |
| FY2018 | -$11.5M | +31.0% |
| FY2017 | -$16.6M | -20.6% |
| FY2016 | -$13.8M | +17.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026